Dalpiciclib combined with endocrine therapy for patients with HR+/HER2− metastatic breast cancer: a multicenter real-world study Authors: Xuelian Chen, Lin Lin, Guangning He, Guanghui Ren, Jiayi Huang, Liping Chen, Xiaofeng Lan, Xiaofeng Xie, Lin Song, Xue Bai, Caiwen Du Published: 2026 ABSTRACT AbstractBackground:Dalpiciclib is the latest cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved in China. Real-world data regarding the efficacy and safety of dalpiciclib for metastatic breast cancer (MBC) are still insufficient.Objectives:This study aims to investigate the real-world outcomes of dalpiciclib in a more heterogeneous population of patients with MBC.Design:We retrospectively collected data of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) MBC patients who received dalpiciclib plus endocrine therapy (ET) between January 2022 to March 2025 from four clinical centers in South China.Methods:Demographic characteristics and clinical data were collected. Real-world progression-free survival (rwPFS), objective response rate (ORR), and safety profiles were analyzed.Results:In total, 160 patients were included. The median follow-up time was 17.6 months (95% confidence interval (CI): 15.0–20.2). The estimated overall median rwPFS was 20.6 months (95% CI: 12.4–28.8), and the ORR was 17.5% (28/160) for the entire cohort. Subgroup analysis showed that the median rwPFS was 26.7 months in patients receiving first-line dalpiciclib plus ET, compared with 13.8 months in those receiving second- or later-line treatment. The median rwPFS for patients with brain metastases (BMs; n = 13) was 14.8 months (95% CI: 4.0–25.6), and the median rwPFS for patients treated by prior CDK4/6 inhibitors (n = 33) was 7.2 months. Stratified Cox regression analysis revealed that the presence of de novo metastatic disease was an independent factor for an increased risk of disease progression (hazard ratio 0.47, 95% CI: 0.25–0.91, p = 0.025). Hematologic toxicity was the most frequent adverse event associated with dalpiciclib treatment.Conclusion:In this real-world cohort of HR+/HER2− MBC patients, dalpiciclib plus ET retains its favorable clinical activity. This regimen also showed promising activity in patients with BMs and those previously exposed to CDK4/6 inhibitors.Keywords: breast cancer, CDK4/6 inhibitors, dalpiciclib, efficacy, real-world Introduction Breast cancer is the leading malignancy in women worldwide. Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) breast cancer accounts for nearly 70% of patients and is responsible for the majority of breast cancer-related deaths.1,2 For decades, endocrine therapy (ET) has been the preferred treatment for HR+/HER2− metastatic breast cancer (MBC). The introduction of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors has transformed the treatment landscape of HR+/HER2− breast cancer.3,4 CDK4/6 inhibitors interrupt proliferation of tumor by inhibiting the kinase activity of the CDK/cyclin complex and arresting the cell-cycle transition from the G1 to the S phase. To date, a total of four CDK4/6 inhibitors, namely palbociclib, abemaciclib, ribociclib, and dalpiciclib, have been approved for use in HR+/HER2− MBC patients by the National Medical Products Administration of China. Multiple phase III randomized controlled trials have confirmed that, whether administered as first-line or later-line therapy, all four CDK4/6 inhibitors yield substantial improvements in progression-free survival (PFS) and tumor response rates compared with ET alone.5–13 Dalpiciclib (SHR6390) was approved in China in December 2021. It is a novel, highly selective CDK4/6 inhibitor with noteworthy antitumor activity (half maximal inhibitory concentration = 12.4 nM for CDK4 and 9.9 nM for CDK6).14,15 The supporting clinical data mainly come from two phase III clinical trials, DAWNA-1 and DAWNA-2.12,13 In the DAWNA-1 study, the addition of dalpiciclib to fulvestrant significantly prolonged investigator-assessed PFS (15.7 vs 7.2 months, hazard ratio (HR) 0.42, p < 0.001) after disease progression of ET for HR+/HER2− MBC. In the DAWNA-2 study, dalpiciclib plus letrozole or anastrozole obtained a median PFS as long as 30.6 months in first-line treatment, making it a potent alternative CDK4/6 inhibitor. However, data on dalpiciclib regarding efficacy in MBC are still scarce outside clinical trials. Owing to the strict inclusion criteria and the inherent heterogeneity in clinical characteristics of patients, evidence derived from randomized clinical trials (RCTs) may have limited generalizability in the broader patient population in routine clinical care. Hence, we carried out this real-world study to examine the treatment efficacy of dalpiciclib combined with ET and explore potential factors associated with its efficacy in HR+/HER2− MBC patients in South China. Materials and methods Data collection and study design This is a retrospective, multi-institutional study that enrolled patients with MBC who were treated with dalpiciclib combined with ET in first-line treatments and subsequent lines of therapy between January 2022 and March 2025. Patients were recruited from four clinical centers in South China, including Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Shenzhen Second People’s Hospital; Dongguan People’s Hospital and Shenzhen Hospital of Southern Medical University. Electronic medical records were retrospectively collected and reviewed from the hospital’s clinical information system. This study was conducted in accordance with the Declaration of Helsinki, and the study protocol and all amendments were reviewed and approved by the Institutional Review Board and China Ethics Committee of the registering clinical trials (Approved No. ChiECRCT 20220108). Informed consent was waived due to the observational and retrospective nature of the study. Detailed enrollment criteria were as follows: (1) Women aged ⩾18 years at the time of MBC diagnosis; (2) Women diagnosed with HR+/HER2− MBC, where HER2 negativity was confirmed by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) in primary or metastatic tissue. HER-zero expression was defined as an IHC score of 0 for HER2, whereas HER2-low expression was defined as HER 1+ or 2+ expression by IHC and lack of HER2 gene amplification measured by FISH; (3) Patients who had received at least one tumor assessment based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1), with response assessment performed at an interval of 8–16 weeks. No restrictions were imposed on the number of previous treatments for metastatic disease, and prior use of other CDK4/6 inhibitors was allowed. Patients with low estrogen receptor (ER) expression were also included. Patients were excluded if they were diagnosed with other concurrent malignancies. Patients discontinuing dalpiciclib therapy or lost to follow-up were also excluded. This study adheres to the STROBE guidelines for reporting observational cohort studies 16 (Supplemental Material). Baseline demographic characteristics (including age, menopausal status), clinical characteristics, Eastern Cooperative Oncology Group performance status (ECOG PS), sites of metastases, previous treatment, endocrine treatment sensitivity, combined drugs, adverse events (AEs), and date of last follow-up in the metastatic setting were collected. Descriptive statistics were used for all the variables of interest. The primary endpoint of this analysis was to examine the real-world PFS (rwPFS), defined as the time interval between the initiation of dalpiciclib and endocrine treatment to the detection of disease progression (assessed by radiological findings, clinical evaluations (including clinical tumor measurements or deterioration of patient symptoms), or death from any cause). Patients without an rwPFS event were censored at the time of data cut-off or last follow-up, whichever occurred first. Overall survival (OS) was defined as the time interval between the initiation of dalpiciclib and the occurrence of death from any cause. Objective response rate (ORR) was defined as the percentage of patients who achieved complete remission (CR) or partial remission. Median rwPFS was assessed by Kaplan–Meier curves. First, a univariable Cox proportional hazards regression model was used to investigate the association of acknowledged prognostic variables and rwPFS; HRs and their corresponding 95% confidence intervals (CIs) were reported for each covariate. Subsequently, variables with a log-rank p-value < 0.10 were included in the multivariable Cox proportional hazards regression analysis. Since the Schoenfeld residual test indicated that the categorical variable “lines of treatment” violated the proportional hazards assumption (p < 0.05), a stratified Cox regression was performed with “lines of treatment” as the stratifying variable. The results showed that the proportional hazards assumption was satisfied for all other covariates (all p > 0.05) after stratification, and the stratified model was used for final analysis. Missing data were entered into models as a separate category. Variables were excluded if they had a missing value rate over 30%. All AEs were graded according to the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE 4.0). All statistics were performed using SPSS27.0. All reported p values (significant cut-off < 0.05) were two-sided. Results Baseline characteristics of the study population A total of 191 patients with HR+/HER2− MBC from 4 clinical centers were screened. Among these, 16 patients were excluded for receiving other anti-tumor drugs combined with dalpiciclib and ET, and 15 patients were deemed ineligible for lack of follow-up, resulting in a final study cohort of 160 patients. By the study data cut-off date of June 30, 2025, the median follow-up duration was 17.6 months (95% CI: 15.0–20.2). Among all 160 patients treated with dalpiciclib, the median age was 57 years (range: 31–80 years). Of these patients, 56 (35.0%) were premenopausal, and 40 (25.0%) patients were aged ⩾65. Approximately half of the patients (53.8%, 86/160) had a favorable ECOG PS score of 0. HER2-zero IHC expression was observed in 35.6% (57/160) of patients, while 64.4% of patients had HER2-low IHC expression. In addition, 33.8% of patients exhibited de novo metastatic disease. A total of 82 (51.3%) patients had visceral metastases, while 8.1% (13/160) of them had brain metastases (BMs). For the 160 enrolled patients, the median number of previous therapies in the metastatic setting was 1 (range: 0–10), and 75 (46.9%) of them had received chemotherapy as prior palliative therapy. Furthermore, 87 (54.4%) patients had taken dalpiciclib plus ET as first-line therapy and 73 (45.6%) patients received it as second- or later-line treatment. With regard to concomitant endocrine drugs, 58 patients (36.2%) were treated with aromatase inhibitors (AIs), and 102 patients (63.8%) with fulvestrant. All premenopausal patients received ovarian function suppression in combination with ET and dalpiciclib. Details of baseline characteristics are presented in Table 1. Table 1.Patient characteristics in the overall study population.CharactersTotal population (n = 160)First-line (n = 87)Second and later-line (n = 73)Menopausal status Premenopausal56 (35.0)33 (37.9)23 (31.5) Postmenopausal104 (65.0)54 (62.1)50 (68.5)Tumor grade 1–286 (53.8)49 (56.3)37 (50.7) 340 (25.0)21 (24.1)19 (26.0) Unknown34 (21.2)17 (19.5)17 (23.3)Ki-67 <30%77 (48.1)38 (43.7)39 (53.4) ⩾3071 (44.4)42 (48.3)29 (39.7) Unknown12 (7.5)7 (8.0)5 (6.9)Hormone receptor status ER+/PgR+133 (83.1)72 (82.8)61 (83.6) ER−/PgR+1 (0.6)0 (0.0)1 (1.3) ER+/PgR−26 (16.3)15 (17.2)11 (15.1)HER2 expression 057 (35.6)31 (35.6)26 (35.6) Low103 (64.4)56 (64.4)47 (64.4)ECOG performance status 086 (53.8)49 (56.3)37 (50.7) ⩾174 (46.2)38 (43.7)36 (49.3)De novo metastatic disease Yes54 (33.8)32 (36.8)22 (30.1) No106 (66.2)55 (63.2)51 (69.9)Visceral metastasis Yes82 (51.2)43 (49.4)39 (53.4) No78 (48.8)44 (50.6)34 (46.6)Brain metastasis Yes13 (8.1)5 (5.7)8 (11.0) No147 (91.9)82 (94.3)65 (89.0)Previous chemotherapy for metastatic disease Yes75 (46.9)39 (44.8)36 (49.3) No85 (53.1)48 (55.2)37 (50.7)Endocrine resistance Primary25 (15.6)9 (10.3)16 (21.9) Secondary135 (84.4)78 (89.7)57 (78.1)Prior CDK4/6 inhibitors Abemaciclib9 (6.3)3 (3.4)6 (9.6) Palbociclib23 (15.0)2 (2.3)21 (30.1) Both1 (0.6)0(0.0)1 (1.4)Drugs combined with dalpiciclib AIs58 (36.2)39 (44.8)19 (26.0) Fulvestrant102 (63.8)48 (55.2)54 (74.0)AI, aromatase inhibitors; CDK4/6, cyclin-dependent kinase 4/6; ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2. Patient characteristics in the overall study population. AI, aromatase inhibitors; CDK4/6, cyclin-dependent kinase 4/6; ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2. Real-world tumor response At the time of survival data cut-off, tumor responses were unavailable for 2 patients, and 65 PFS events had occurred. In the total study population, the ORR was 17.5% (28/160), including 4 (2.5%) with CR. A total of 79 (49.4%) patients had stable disease for more than 6 months, while 17 (10.8%) patients had confirmed progressive disease. The ORR was 19.5% in patients receiving dalpiciclib combined with ET as first-line treatment, and 15.1% in those receiving it as second-line or later-line treatment; the difference between the two groups was not statistically significant (p = 0.757). The estimated median rwPFS was 20.6 months (95% CI: 12.4–28.8; Figure 1) for the full cohort. Subgroup analyses indicated that the median rwPFS was 26.7 months (95% CI: 15.8–37.6) in patients with first-line dalpiciclib plus ET, which was much longer than the 13.8 months (95% CI: 0.0–27.6) observed in those treated with second- or later-line dalpiciclib (p = 0.008). In addition, patients with de novo metastatic disease at diagnosis obtained a longer rwPFS than those not (not reached; NR vs 17.3months, p = 0.013). Similarly, patients who received dalpiciclib combined with AIs had a prolonged rwPFS relative to those receiving fulvestrant (NR vs 17.3 months, p = 0.021). Although a numerical difference in rwPFS was noted between patients with HER2-zero and HER2-low expression (37.5 vs 20.1 months), the difference was not significant (p = 0.766). Other factors such as menopausal status, tumor grade, ki67, and ECOG PS did not have an influence on the rwPFS. Results of the subgroup analyses are illustrated in Table 2 and Figure 2. Stratified Cox regression analysis identified that the presence of de novo metastatic disease was an independent factor for an increased risk of disease progression (HR 0.47, 95% CI: 0.25–0.91, p = 0.025). The OS data were still not available, with only a total of 11 deaths recorded. Progression-free survival of dalpiciclib combined with endocrine therapy stratified by patient characteristics. (a) Total population. (b) Menopausal status. (c) Tumor grade. (d) Ki67. (e) HER2 expression. (f) ECOG score. (g) Presence or absence of de novo metastatic disease. (h) Prior chemotherapy for MBC. (i) Treatment line of dalpiciclib for MBC. (j) Primary versus secondary endocrine resistance. (k) Prior use of CDK4/6 inhibitors. (l) Drugs combined with dalpiciclib. (m) Presence or absence of visceral metastases. (n) Presence or absence of brain metastases. CDK4/6, cyclin-dependent kinase 4/6; ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; MBC, metastatic breast cancer. Table 2.Results of univariate Cox analysis and stratified multivariate regression analysis by lines of treatment for rwPFS.ParameterrwPFS (m)Univariate analysisMultivariate analysisHR (95% CI)p-ValueHR (95% CI)p ValueMenopausal status (Post vs Pre)NR vs 19.10.63 (0.35–1.11)0.104Tumor grade (I–II vs III)20.1 vs 18.50.75 (0.43–1.31)0.311Ki67 (<30% vs ⩾30%)26.7 vs 16.70.67 (0.40–1.12)0.157HER2 expression (zero vs low)37.5 vs 20.10.92 (0.55–1.56)0.766ECOG (0 vs ⩾1)30.0 vs 18.50.80 (0.49–1.30)0.369De novo metastatic disease (yes vs no)NR vs 17.30.47 (0.26–0.87) 0.013 0.47 (0.25–0.91) 0.025 Chemotherapy for metastatic disease (no vs yes)22.6 vs 18.50.94 (0.58–1.52)0.790Lines of treatment (first-line vs second or later line)26.7 vs 13.80.52 (0.32–0.85)0.008N/AN/AEndocrine resistance (secondary vs primary)26.7 vs 16.70.59 (0.33–1.06) 0.074 0.70 (0.38–1.29)0.25Visceral disease (no vs yes)30.0 vs 14.80.62 (0.38–1.03) 0.061 0.67 (0.39–1.14)0.14Brain metastases (no vs yes)22.6 vs 14.80.67 (0.30–1.45)0.311Prior CDK4/6 inhibitors (no vs yes)26.7 vs 7.20.38 (0.22–0.66) <0.001 0.57 (0.30–1.08)0.09Combined drugs (AI vs Ful)NR vs 17.30.52 (0.30–0.91) 0.021 0.76 (0.41–1.41)0.38AIs, aromatase inhibitors; CDK4/6, cyclin-dependent kinase 4/6; CI, confidence interval; DFS, disease-free survival; ECOG, Eastern Cooperative Oncology Group; Ful, fulvestrant; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; N/A, not applicable; rwPFS, real-world progression-free survival.Bold type indicates variables with p < 0.10 (univariate Cox analysis) and p < 0.05 (multivariate Cox analysis). Results of univariate Cox analysis and stratified multivariate regression analysis by lines of treatment for rwPFS. AIs, aromatase inhibitors; CDK4/6, cyclin-dependent kinase 4/6; CI, confidence interval; DFS, disease-free survival; ECOG, Eastern Cooperative Oncology Group; Ful, fulvestrant; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; N/A, not applicable; rwPFS, real-world progression-free survival. Bold type indicates variables with p < 0.10 (univariate Cox analysis) and p < 0.05 (multivariate Cox analysis). Forest plot of subgroup analyses of PFS. PFS, progression-free survival. Patients with BMs There were 13 patients with stable BM in the whole cohort at baseline, including 5 patients treated in the first-line setting and 8 in the second- or later-line setting. All patients had prior local therapy before dalpiciclib, including radiotherapy (n = 10) and surgery (n = 3). Only two patients experienced disease progression at the first tumor evaluation. The median rwPFS of patients with BMs was 14.8 months (95% CI: 4.0–25.6), which was numerically shorter than that in patients without brain involvement (22.6 months; 95% CI: 14.3–40.0), although the difference was not statistically significant (p = 0.311). Patients pretreated by CDK4/6 inhibitors In this study, we also included 33 patients who had been treated with CDK4/6 inhibitors. Nine of them had received abemaciclib, including 3 in the adjuvant setting; 23 patients had received palbociclib before dalpiciclib, and 1 had been exposed to both abemaciclib and palbociclib. Twenty-two patients received dalpiciclib immediately after disease progression on prior CDK4/6 inhibitors, while 11 patients received other intervening treatments before switching to dalpiciclib. Within this subgroup, 24 patients took dalpiciclib as first- or second-line treatment, and 22 patients had visceral disease. The ORR was 12.5% (4/33). The median rwPFS of this subgroup of patients was much shorter compared to those without prior CDK4/6 inhibitor exposure (7.2 vs 26.7 months, p < 0.001). Safety By the cut-off date, 90 patients remained on dalpiciclib-based treatment. Overall, 153 (95.6%) patients experienced at least 1 any-grade AE. The most common AEs were neutropenia (85.0%), anemia (60.0%), fatigue (39.4%), anorexia (36.9%), thrombocytopenia (30.0%), skin rash (25.6%), and mucositis (21.2%). Grade ⩾3 AEs occurred in 49.4% of the total population, and grade 3–4 toxicities were predominantly hematologic; the most frequent grade ⩾3 hematologic AEs were neutropenia (48.7%) and thrombocytopenia (5.0%). Dose reduction attributable to AEs occurred in 37 patients (23.1%), and treatment discontinuation was reported in 2 patients (1.3%). One case was caused by grade 3 skin rash, and the other by recurrent grade 4 neutropenia. A comprehensive summary of AEs is presented in Table 3. Table 3.Most frequently reported AEs.AEsAll grades, N (%)Grade 3–4, N (%)Neutropenia136 (85.0)76 (48.7)Anemia96 (60.0)1 (0.6)Thrombocytopenia48 (30.0)8 (5.0)Elevated ALT/AST25 (15.6)1 (0.6)Fatigue63 (39.4)0 (0.0)Skin rash41 (25.6)1 (0.6)Mucositis34 (21.2)0 (0.0)Diarrhea8 (5.0)0 (0.0)Anorexia59 (36.9)1 (0.6)AEs, adverse events; ALT, alanine aminotransferase; AST, aspartate aminotransferase. Most frequently reported AEs. AEs, adverse events; ALT, alanine aminotransferase; AST, aspartate aminotransferase. Discussion A series of pivotal studies (MONALEESA, MONARCH, and PALOMA) have demonstrated highly consistent PFS benefit from the addition of CDK4/6 inhibitors (ribociclib, abemaciclib, and palbociclib, respectively) to ET.6–11 These results were subsequently validated by plenty of real-world studies later.17–19 Dalpiciclib is the latest CDK4/6 inhibitor approved in China; however, only two randomized controlled trials of dalpiciclib (DAWNA-1 and DAWNA-2) and one retrospective analysis 20 with a small sample size (n = 42) have been reported in the literature. In this real-world report, we aimed to expand on the efficacy and safety data of dalpiciclib in a more heterogeneous population. To the best of our knowledge, the current study is the first real-world analysis focusing on dalpiciclib combination therapy for HR+/HER2− MBC. The overall rwPFS was 20.6 months, and the presence of de novo metastatic disease was an independent poor factor for rwPFS. These survival data are comparable to the outcomes with the use of dalpiciclib and other CDK4/6 inhibitors in RCTs. Our study revealed a median rwPFS of 26.7 months in first-line treatment, which was numerically slightly lower than the 30.6 months of observed for first-line dalpiciclib plus letrozole or anastrozole in the DAWNA-2 clinical trial. Although direct cross-study comparisons are not advisable, distinct differences in baseline characteristics can still be discerned compared with the DAWNA-2 trial. Our study population exhibited a lower rate of patients with de novo metastatic disease at diagnosis (36.8% vs 41.0%). Meanwhile, a higher proportion of patients in our study (44.8%) had received induction chemotherapy prior to dalpiciclib treatment in the metastatic setting, compared with 0.0% in the DAWNA-2 trial. Additionally, patients with poor prognostic factors (BMs, prior CDK4/6 inhibitors) were ineligible and excluded from the DAWNA-2 trial, but were included in our real-world study. These differences may have led to an underestimation of rwPFS. Unlike RCTs, real-world cohorts could better resemble the total population, and offer a better picture of clinical outcomes. A key strength of our study lies in the generation of expanded real-world evidence. First, our study cohort included 13 MBC patients with BMs, who were all pretreated and with stable BMs. Preclinical evidence has indicated that CDK4/6 inhibitors were capable of crossing the blood-brain barrier.21–24 For example, abemaciclib could reach therapeutic concentrations in BMs tissue, which was far exceeding those necessary to inhibit CDK4 and CDK6. 25 Although most RCTs of CDK4/6 inhibitors did not exclude patients with BMs, there is limited evidence to inform their central nervous system (CNS) efficacy. In the phase II study of abemaciclib for HR+/HER2− MBC with BMs, the intracranial ORR was only 5.2%, the median OS was 12.5 months, and the study did not meet its primary endpoint. 25 CNS-specific activity of dalpiciclib has not been reported before. The rwPFS was as long as 14.8 months for patients with BMs in our study, indicating the potential of CNS-specific activity of dalpiciclib. Relevant clinical trials to appropriately evaluate CNS-specific response of dalpiciclib are still needed. Second, 33 patients included in our study had been pretreated by other CDK4/6 inhibitors (abemaciclib or palbociclib). Continuation of CDK4/6 inhibition has become a compelling treatment option after progression on prior CDK4/6 inhibitors, but the results of these studies are not consistent. Generally, modest survival benefit has been observed by switching to a different CDK4/6i after progression compared to ET alone in the MAINTAIN trial and postMONARCH trial,26,27 while continuation of the same CDK4/6 inhibitor28,29 (palbociclib after palbociclib in the PACE and PALMIRA trials) showed no improvement of PFS. The median rwPFS of dalpiciclib for cross-line treatment in our study was 7.2 months, which was numerically longer than data (5.3–6.0 months) from previously published studies in the MAINTAIN trial and postMONARCH trial.26,27 This difference may be attributed to the patient population in our study: a great percentage of patients used dalpiciclib as earlier-line of treatment (9.1% (3/33) of them received CDK4/6 inhibitors in the adjuvant setting, and 72.7% (24/33) of patients took dalpiciclib as first or second-line treatment). Although cross-line use of CDK4/6 inhibitors after CDK4/6 inhibitor progression is far from being a standard of care, our findings point to the fact that switching to dalpiciclib and ET after other CDK4/6i could serve as a suitable maintenance option for selected patients. What’s more, we assessed the predictive value of HER2-low expression for PFS during treatment of dalpiciclib and ET. Despite the absence of gene amplification, the crosstalk between HER2 and hormone receptor pathways can modulate HER2 expression, indicating the existence of ET resistance related to HER2 low expression. 30 While some studies found similar outcomes between HER2-low and HER2-zero breast cancer during treatment of CDK4/6 inhibitors and ET,31,32 others found that low-level expression of HER2 was associated with an inferior PFS during CDK 4/6 inhibitors.33–36 A preclinical study showed that adding the anti-HER2 drug neratinib could enhance the efficacy of CDK4/6 inhibitors combined with ET in HR+/HER2-low breast cancer in vitro. 37 In our study, HER2 status did not significantly influence PFS of the dalpiciclib and ET; the difference was only numerical (37.5 vs 20.1 months, p = 0.766). More studies should provide insights into the potential role of integrating HER2 status as a potential marker candidate for CDK4/6 inhibitors and ET. Hematologic toxicity is the most frequent AE of dalpiciclib. In our real-world study, the incidence of neutropenia (85.4%) of dalpiciclib plus ET seemed to be lower than that in the DAWNA trials (97.9%–99.0%), and the same held true for thrombocytopenia (29.1% vs 49.0%–56.3%). The lower incidence of hematologic toxicity in our study compared with randomized controlled trials may be explained by several factors. First, passive surveillance in real-world practice failed to capture mild and asymptomatic events. Second, physicians tended to avoid using the drug or reduced the dosage at initiation of dalpiciclib in high-risk populations, resulting in selection bias or lower-dosage of drug exposure. Finally, loss to follow-up might further contribute to the underestimation of adverse reactions. Despite several advantages, our study has certain limitations to be acknowledged. First, this is a retrospective real-world study; selection bias inevitably exists. Second, the relatively small sample size limits the generalizability of our findings. In particular, results from the subgroup comparisons should be interpreted with caution and recognized as exploratory. Third, data on PI3K/AKT/mTOR pathway alterations and ESR1 mutations were not available in most of the patients. Fourth, the median OS has not been reached and longer follow-up periods are required to fully evaluate long-term outcomes. Currently, CDK4/6 inhibitors have been widely adopted in clinical practice, with an increasing number of novel agents continuously springing up. Although the anti-tumor efficacy of these CDK4/6 inhibitors is generally comparable, notable differences exist in their brain penetration capacity, safety profiles including AEs, and dosing regimens. As a novel CDK4/6 inhibitor, dalpiciclib exhibits distinct pharmacological and clinical characteristics, thereby providing a valuable option to further optimize individualized treatment strategies for patients. Conclusion In conclusion, our study is the first real-world analysis focused on dalpiciclib combination therapy for HR+/HER2− MBC. The efficacy of dalpiciclib and ET was confirmed in an expanding body of patients. Supplemental Material sj-docx-1-tam-10.1177_17588359261467382 – Supplemental material for Dalpiciclib combined with endocrine therapy for patients with HR+/HER2− metastatic breast cancer: a multicenter real-world study Supplemental material, sj-docx-1-tam-10.1177_17588359261467382 for Dalpiciclib combined with endocrine therapy for patients with HR+/HER2− metastatic breast cancer: a multicenter real-world study by Xuelian Chen, Lin Lin, Guangning He, Guanghui Ren, Jiayi Huang, Liping Chen, Xiaofeng Lan, Xiaofeng Xie, Lin Song, Xue Bai and Caiwen Du in Therapeutic Advances in Medical Oncology